Value-Based Healthcare: Integration of Real World Evidence
- FRIDAY, October 22, 2021
- Panel: Value-Based Healthcare: Integration of Real World Evidence
It is generally accepted that no healthcare system in the world is economically sustainable, and with the threat of the silver tsunami, it is only going to get more precarious. In order to bring spending under control value-based healthcare or healthcare delivered reimbursed on outcomes rather than service. However, healthcare systems have not been set up to capture outcome metrics that can demonstrate value delivered. At the same time, the quantity of health data has reached new heights in recent years due to the increased use of health apps, computers, electronic health records, biometric trackers, biomarker analysis and remote patient monitoring devices. Extraordinarily, these data sets are collected in real time, making up an unstructured set of “real-world data” (RWD). Once structured and analyzed, RWD can provide real-world evidence (RWE). Together, they are recognized by regulators as having the potential to inform across the entire healthcare ecosystem including the value of the care delivered by evaluating treatment outcomes and safety. They can also help design better and more efficient clinical trials and care provisions. The impact potential is relative to the quality and quantity of RWD/ RWE available and to the engagement and acceptance by the members of the ecosystem. The panel will explore how members of this ecosystem can capture and integrate RWD/RWE into reimbursement models and the decision-making processes to improve care and efficiencies across the care continuum.
Moderator: Dr. Rob Fraser, President & CEO, Molecular You
Dr. Robert Fraser is the President and CEO of Molecular You, a digital health company delivering molecular-level personalized health insights and action plans. Dr. Fraser has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. He is the co-founder of The Personalized Medicine Initiative (PMI), GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind. Dr. Fraser has led drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD and has been involved in raising of more than $37M in funding. He completed his Ph.D. in the molecular mechanisms of endocrinology at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg France.
Meet The Expert Speakers:
- Mo Amin, Vice President, Value, Access & Policy, AstraZeneca Canada
Mo Amin is the Vice President of Value, Access & Policy at AstraZeneca Canada Inc., one of Canada’s leading biopharmaceutical companies. Mo brings to the position more than 25 years’ experience in the biopharmaceutical industry, including extensive experience within the areas of Market Access, Medical Affairs, Health Economics and Real World Evidence (RWE).
His career spans roles in academia and both the private and public sector. Among some of the positions Mo has held include Adjunct Professor, Department of Medicine – University of Ottawa; Scientific Advisor – Common Drug Review (CDR) and Canadian Agency for Drugs and Technologies in Health (CADTH); and Regional Head of Global Health Economics, Epidemiology & RWE – Intercontinental Region, Amgen and Head of Value & Access, Amgen Canada.
Prior to joining AstraZeneca, Mo was Regional Head & VP of Medical Access for the Intercontinental region at Sanofi, leading medical, access and evidence generation strategies for Asia, Africa, Middle East and China regions.
Mo is a trained medical doctor with a PhD in Health Economics from the University of London. Mo lives in Milton with his wife Beenish and three children.
- Dr. Dean Regier, Senior Scientist, Cancer Control Research, BC Cancer
Dr. Regier is a Senior Scientist within Cancer Control Research, BC Cancer, and an Associate Professor at the School of Population and Public Health, Faculty of Medicine, University of British Columbia. Over the past 15 years, Dr. Regier’s research has focused on the economics of access to precision medicine, particularly in context to generating and using real world evidence to support sustainable regulatory and learning healthcare systems. He has presented his work internationally, with invitations from the US National Academies of Sciences and the World Economic Forum. He is Deputy Editor at the International Journal of Technology Assessment in Health Care and currently serves on BC’s Drug Benefit Council, which makes evidence-informed recommendations to the Ministry of Health about the listing of drugs on the PharmaCare program formulary.
- Dr. Winson Cheung, Senior Medical Oncologist, Principal Director, Oncology Outcomes (O2)
Dr. Cheung is a medical oncologist and a nationally and internationally recognized data scientist and researcher. He is currently a Professor of Medicine in the Departments of Medicine and Oncology at the University of Calgary in Canada where he is the Provincial Director of Health Services Research and Real-World Evidence Generation for Cancer Care Alberta. In these roles, he works frequently with “big data”, including data from administrative claims, large registries, and electronic health records.
Dr. Cheung’s primary academic interest is health services and outcomes research, including patient reported outcomes, quality of life, and economic analyses that span the entire real-world evidence spectrum. The overarching goal of his work is to ensure that cancer care is appropriately accessed and equitably delivered to all patients. He also evaluates ways to improve the uptake of novel drugs and examines strategies that enhance their adoption to ensure that we achieve value-based care. Currently, he leads the well-established and prolific Oncology Outcomes (O2) research collaborative, which has published 200+ manuscripts and $5M+ in grant funding.
- Janey Shin, Director, Patient Value Innovation, Janssen
Janey Shin is the Director, Patient Value Innovation at Janssen Inc. in Canada. She is responsible for leading patient-centric, data-driven innovation and accelerating the design and implementation of integrated solutions to deliver differential value to patients. Prior to this role, Janey was the Director, Real World Evidence where she was responsible for developing the Janssen RWE strategy for Canada and for driving high priority evidence research projects through partnerships with healthcare, government, academic, research, and data provider organizations. Prior to Janssen, Janey was the Director of Medical Affairs at Johnson & Johnson Medical Companies Canada, where she lead the development and execution of Medical Education, Clinical Affairs, Health Economics and Market Access, and Medical Information strategies across all franchise portfolio of medical device products. Prior to Johnson & Johnson, she was the Director of Analytics and Surveillance at the Canadian Partnership Against Cancer and was responsible for driving key oncology pan-Canadian initiatives, including enhancing surveillance systems, developing health economic system decision-making tools, and building analytic capacity through engagement and partnerships with federal, provincial, and territorial stakeholders. Over the last two decades, Janey has had progressive roles in statistics, clinical operations, sales and marketing operations, and Lean Six Sigma. Janey holds an MBA from the Rotman School of Management, a Masters in Biostatistics, both from the University of Toronto, and a Bachelor of Science in Actuarial Science from the University of Western Ontario.